2010-2024年 Medicare 乳房手术报销趋势:全国与地理分析
研究分析2010-2024年6种乳房手术的 Medicare 报销数据,按 CPI 调整至2024年美元。结果显示所有术式报销实际下降,范围从 -26.0%(乳房固定术)至 -46.2%(组织扩张器重建),且地理调整未能充分反映生活成本与地方通胀差异。
要点
- 2010-2024年所有乳房手术 Medicare 报销经通胀调整后均下降,植入物重建降幅最大。
- 高成本城市报销溢价(-9.5%至+16.7%)远小于生活成本溢价(-12.2%至+131.0%)。
- 地方通胀差异(-6.3至+12.6个百分点)未与报销趋势成比例对应。
核心结论
- 2010-2024年乳房手术 Medicare 报销经通胀调整后大幅下降,植入物重建损失最重。
- 地理调整虽提高高成本城市支付,但未充分覆盖生活成本或地方通胀差异。
- 报销趋势常滞后于区域经济状况,引发对执业可持续性和重建公平可及性的担忧。
研究设计与样本
- 从 Medicare Physician Fee Schedule 获取2010-2024年6种乳房手术的报销数据。
- 全国报销率按 CPI 调整至2024年美元,并计算自2010年累计百分比变化。
- 横断面分析20个最大美国城市的地方 MAC 费率与城市 COLI 值。
- 对拥有都市 CPI 数据的城市,比较城市级通胀与报销变化同全国趋势。
主要发现
- 2010-2024年所有术式报销经通胀调整后下降,范围从 -26.0%(乳房固定术)至 -46.2%(组织扩张器重建)。
- 生活成本溢价范围 -12.2%(印第安纳波利斯)至 +131.0%(纽约),报销溢价仅 -9.5%(印第安纳波利斯)至 +16.7%(圣何塞)。
- 高成本城市报销通常更高,但报销差异幅度远小于生活成本差异。
- 都市 CPI 数据城市中,通胀差异相对全国为 -6.3至+12.6个百分点,报销差异为 -3.5至+3.4个百分点。
- 通胀最高的城市(如西雅图、丹佛)未经历成比例有利的报销趋势。
临床怎么用
- 整形与烧伤科医生应知晓乳房手术 Medicare 报销实际价值持续下降,尤其植入物重建。
- 在高成本或通胀快速城市执业者需预期更大实际报销损失,规划执业可持续性。
- 关注地理调整不足对重建手术公平可及性的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medicare reimbursements have stagnated or declined despite rising practice costs. Because regional adjustments through the Geographic Practice Cost Index (GPCI) only partially account for cost variation, surgeons in high-cost or rapidly inflating cities may experience greater real losses in reimbursement. Breast procedures offer a high-volume proxy for evaluating national and geographic changes in plastic surgery Medicare payments. This study aimed to quantify national Medicare reimbursement trends for breast procedures and to examine city-level differences in reimbursement relative to local cost of living and inflation. METHODS: Medicare reimbursement data for 6 breast procedures were obtained from the Medicare Physician Fee Schedule (2010-2024): mastopexy, reduction mammoplasty, immediate implant reconstruction, delayed implant reconstruction, tissue expander reconstruction, and free flap reconstruction. National reimbursement rates were inflation adjusted to 2024-dollars using the Consumer Price Index (CPI) and expressed as cumulative percentage change from 2010. Geographic reimbursement and cost of living was evaluated cross-sectionally using locality-specific Medicare Administrative Contractor (MAC) rates and city-level Cost of Living Index (COLI) values for the 20 largest US cities. For cities with metropolitan CPI data, city-level inflation and reimbursement changes were compared with national trends. RESULTS: From 2010 to 2024, Medicare reimbursement declined for all procedures after adjusting for inflation, ranging from -26.0% (mastopexy) to -46.2% (tissue expander reconstruction). Cross-sectionally, cost-of-living premiums ranged from -12.2% (Indianapolis) to +131.0% (New York), while reimbursement premiums only ranged from -9.5% (Indianapolis) to +16.7% (San Jose). Although higher-cost cities generally had higher reimbursement, the magnitude of reimbursement differences was far smaller than the cost-of-living differences. Among cities with metropolitan CPI data, inflation differentials ranged from -6.3 to +12.6 percentage points relative to the national rate, while reimbursement differentials ranged from -3.5 to +3.4 percentage points. Cities with the highest inflation (eg, Seattle, Denver) did not experience proportionally favorable reimbursement trends. CONCLUSIONS: Inflation-adjusted Medicare reimbursements for breast procedures declined substantially from 2010 to 2024, with the steepest losses in implant-based reconstruction. Geographic adjustments increased payments in higher-cost cities but did not fully account for differences in cost of living or local inflation. As a result, reimbursement trends often lagged behind regional economic conditions, raising concerns about long-term practice sustainability and equitable access to reconstruction.
引用
- Stigliano M, Gundlach C, Qin N, et al. Trends in Medicare Reimbursement for Breast Procedures: A National and Geographic Analysis, 2010-2024. Ann Plast Surg. 2026. PMID: 41701182. doi:10.1097/SAP.0000000000004646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。